Who
Andrew Callos
EVP, Chief Commercial Officer
Company insider
Files Form 4 as: EVP, Chief Commercial Officer, Cytokinetics.
In numbers
- Trades disclosed
- 160
- Buys
- 0
- Sells
- 31
- Bought
- $0
- Sold
- $31.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Mar 2021
- Last trade
- 31 Aug 2026
- Last filed
- 31 Aug 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 31 Aug 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code M | $233K10,000 at $23.26 | filing |
| 31 Aug 2026filed 31 Aug 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $702K10,000 at $70.24 | filing |
| 31 Aug 2026filed 31 Aug 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 31 Aug 2026filed 31 Aug 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 31 Aug 2026filed 31 Aug 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code M | $233K10,000 at $23.26 | filing |
| 31 Aug 2026filed 31 Aug 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $702K10,000 at $70.24 | filing |
| 30 Jul 2026filed 30 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code M | $326K14,000 at $23.26 | filing |
| 30 Jul 2026filed 30 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $1.1M14,000 at $79.88 | filing |
| 30 Jul 2026filed 30 Jul 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,000 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,000 at $0.00 | filing |
| 30 Jul 2026filed 30 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code M | $326K14,000 at $23.26 | filing |
| 30 Jul 2026filed 30 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $1.1M14,000 at $79.88 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code M | $349K15,000 at $23.26 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $1.3M15,000 at $85.80 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code M | $349K15,000 at $23.26 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $1.3M15,000 at $85.80 | filing |
| 1 Jun 2026filed 1 Jun 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code M | $349K15,000 at $23.26 | filing |
| 1 Jun 2026filed 1 Jun 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Sold | $1.1M15,000 at $74.08 | filing |
News
Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) vs. Cytokinetics (NASDAQ:CYTK)CYTK · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Andrew Callos; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.